Petr Arenberger

11PUBLICATIONS
67CO-AUTHORS
Predictive and prognostic markersTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 27, 2025
Prognostic Biomarkers for Anti-PD-1 Monoclonal Antibodies in the First Line Treatment of Advanced Melanoma.

Marek Pásek, Emanuel Marques, Vojtěch Tretera

|Mar 06, 2025
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).

Adi Diab, Paolo A Ascierto, Michele Maio

|Oct 18, 2024
Long-Term Efficacy and Tolerability of an Emollient Containing Glycerol and Paraffin for Moderate-to-Severe Uremic Xerosis: A Randomized Phase 3 Study.

Jacek C Szepietowski, Lajos Kemeny, Thomas Mettang

|Aug 05, 2024
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.

Jeffrey Weber, Michele Del Vecchio, Mario Mandalá

|Mar 07, 2024
European consensus-based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV-induced dysplasia and field cancerization on behalf of European Association of Dermato-Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Européenne des Médecins Spécialistes).

Lidija Kandolf, Ketty Peris, Josep Malvehy

|Apr 14, 2023
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.

James Larkin, Michele Del Vecchio, Mario Mandalá

Pageof 2

Frequent Collaborators

5 joint publications

Monika Arenbergerová

4 joint publications

Marek Pásek

3 joint publications

Marcus O Butler

3 joint publications

Emanuel Marques